Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Rheumatology

When Colchicine Isn't Enough: IL-1 Inhibitors and Advanced Care

At a Glance

For 5-10% of Familial Mediterranean Fever (FMF) patients, colchicine does not fully control attacks. In these cases of colchicine resistance, IL-1 inhibitors (biologics like anakinra, canakinumab, and rilonacept) are highly effective at blocking the root cause of inflammation.

For the majority of people with Familial Mediterranean Fever (FMF), colchicine is a life-changing treatment. However, for about 5% to 10% of patients, colchicine either doesn’t work well enough to stop the attacks or causes side effects that are too severe to handle [1][2][3].

If you are in this group, it does not mean you are out of options. In recent years, a group of advanced medications called biologics—specifically IL-1 inhibitors—have become the new standard of care for what is known as “resistant” FMF [4][5].

Defining “Colchicine Resistance”

Doctors generally consider FMF to be “colchicine resistant” if you continue to have one or more attacks per month (over a 3-month period) despite taking the maximum dose of colchicine you can tolerate [6][7].

You may also be considered resistant if your blood tests show “silent” or subclinical inflammation (high levels of proteins like CRP or SAA) even when you aren’t currently having a painful attack [6][8].

How IL-1 Inhibitors Work

As we discussed in the biology section, the “glitch” in FMF causes your body to overproduce a powerful inflammatory chemical called Interleukin-1 beta (IL-1β) [9][10].

IL-1 inhibitors are like specialized “sponges” or “shields” that directly target and block this chemical before it can cause fever and pain [10][11]. By stopping the inflammation at its source, these drugs can provide rapid relief and, more importantly, protect your kidneys from long-term damage (amyloidosis) [12][8].

The Three Main Options

These medications are biologics, meaning they are made from living cells. Because they are large proteins, they cannot be taken as a pill (your stomach would just digest them); instead, they are given as subcutaneous injections (shots under the skin) [13].

Medication How it’s taken Notes
Anakinra Daily injection Acts quickly and is often the first choice for short-term flares or severe cases [14][10]. It is very effective but can sometimes cause temporary redness or itching at the injection site [15][16].
Canakinumab Monthly injection The first drug specifically FDA-approved for FMF [17]. Because it lasts longer in the body, it only needs to be injected once every four weeks [13][18].
Rilonacept Weekly injection Another effective “trap” for IL-1 that has been used successfully in patients who don’t respond to other treatments [1][2].

What to Expect

Starting a biologic is a big step, but it is often a turning point for patients who have struggled with frequent flares.

  • Safety: Most patients tolerate these drugs very well. The most common side effects are mild reactions at the injection site (redness or swelling) and a slightly higher risk of common infections like colds [15][19].
  • Monitoring: Your doctor will likely want to check your blood regularly to monitor your inflammatory markers and ensure your immune system is staying healthy [20][19].
  • Cost and Access: These medications are expensive, and your medical team will often need to work closely with your insurance company to secure coverage [14].

Having resistant FMF can feel discouraging, but these advanced therapies offer a powerful way to regain control over your health and protect your future [12][15].

Common questions in this guide

How do I know if I am colchicine resistant?
Doctors generally consider FMF to be colchicine resistant if you continue to have one or more attacks per month over a 3-month period despite taking the maximum tolerated dose. You may also be considered resistant if blood tests show high levels of inflammation between attacks.
How do IL-1 inhibitors work for FMF?
FMF causes your body to overproduce an inflammatory chemical called Interleukin-1 beta (IL-1β). IL-1 inhibitors act like sponges or shields that directly block this chemical before it can cause fever and pain, stopping the inflammation at its source.
What are the different biologic medications for FMF?
The three main IL-1 inhibitors used for FMF are anakinra, canakinumab, and rilonacept. Because they are large proteins made from living cells, they cannot be taken as pills and must be given as injections under the skin.
What are the side effects of IL-1 inhibitors?
Most patients tolerate these medications very well. The most common side effects are mild reactions at the injection site, such as temporary redness or itching, and a slightly higher risk of common infections like the common cold.
Can I stop taking colchicine if I start a biologic medication?
Your doctor will need to evaluate your specific case to determine if you should continue taking colchicine alongside your new biologic medication. Many patients use a combination to ensure maximum protection against inflammation and long-term kidney damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my frequency of attacks, do I officially meet the criteria for 'colchicine resistance'?
  2. 2.Between my painful attacks, are my inflammatory markers (like CRP or SAA) staying high?
  3. 3.What are the pros and cons for me specifically regarding daily injections (anakinra) versus monthly injections (canakinumab)?
  4. 4.What tests do I need to have—such as for tuberculosis or other infections—before I can start a biologic medication?
  5. 5.If I start an IL-1 inhibitor, will I still need to take my daily colchicine, or can I stop it?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Why Do IL-1 Inhibitors Work When Colchicine Fails?

References

References (20)
  1. 1

    Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.

    Gül A

    Best practice & research. Clinical rheumatology 2016; (30(2)):296-303 doi:10.1016/j.berh.2016.09.001.

    PMID: 27886801
  2. 2

    Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.

    Gök K, Cengiz G, Erol K, Ozgocmen S

    Acta reumatologica portuguesa 2017; (42(1)):88-90.

    PMID: 28371574
  3. 3

    [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].

    Shouval R, Livneh A, Ben-Zvi I

    Harefuah 2015; (154(11)):716-9, 741.

    PMID: 26821505
  4. 4

    [Familial mediterranean fever].

    Vinit C

    La Revue du praticien 2023; (73(8)):843-849.

    PMID: 38354004
  5. 5

    Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean fever.

    Sag E, Otón T, Carmona L, Ozen S

    Annals of the rheumatic diseases 2025; (84(11)):1909-1927 doi:10.1016/j.ard.2025.05.020.

    PMID: 40562663
  6. 6

    Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach.

    Özen S, Sag E, Ben-Chetrit E, et al.

    Rheumatology (Oxford, England) 2021; (60(8)):3799-3808 doi:10.1093/rheumatology/keaa863.

    PMID: 33331943
  7. 7

    Colchicine resistance: Associated factors and its effect on health-related quality of life in patients with familial Mediterranean fever.

    Erdem Gürsoy D, Gezer HH, Öz N, et al.

    International journal of rheumatic diseases 2022; (25(11)):1239-1245 doi:10.1111/1756-185X.14407.

    PMID: 35903906
  8. 8

    Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.

    Erkilet HK, Gezgin Yildirim D, Esmeray P, Söylemezoğlu O

    Pediatrics international : official journal of the Japan Pediatric Society 2023; (65(1)):e15588 doi:10.1111/ped.15588.

    PMID: 37658625
  9. 9

    Evaluation of the Effect of IL-1 Antagonists on Pituitary Function.

    Aktas Koc F, Sariakcali B, Sahin A

    International journal of endocrinology 2026; (2026()):8796993 doi:10.1155/ije/8796993.

    PMID: 41531813
  10. 10

    The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.

    Giat E, Ben-Zvi I, Lidar M, Livneh A

    International journal of molecular sciences 2022; (23(7)) doi:10.3390/ijms23073956.

    PMID: 35409316
  11. 11

    Atypical Familial Mediterranean Fever Presenting with Recurrent Upper Back Pain: A Case Report.

    Matsumoto H, Saito K, Sumichika Y, et al.

    The Tohoku journal of experimental medicine 2023; (260(2)):165-169 doi:10.1620/tjem.2023.J030.

    PMID: 37045785
  12. 12

    IL1-blocking therapy in colchicine-resistant familial Mediterranean fever.

    Köhler BM, Lorenz HM, Blank N

    European journal of rheumatology 2018; (5(4)):230-234 doi:10.5152/eurjrheum.2018.18036.

    PMID: 30501849
  13. 13

    IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations.

    Kharouf F, Tsemach-Toren T, Ben-Chetrit E

    Clinical and experimental rheumatology 2022; (40(8)):1567-1574 doi:10.55563/clinexprheumatol/obb2ds.

    PMID: 36062765
  14. 14

    The clinical role of anakinra in the armamentarium against familial Mediterranean fever.

    Parlar K, Ates MB, Egeli BH, Ugurlu S

    Expert review of clinical immunology 2024; (20(5)):441-453 doi:10.1080/1744666X.2023.2299230.

    PMID: 38133629
  15. 15

    The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.

    Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S

    Frontiers in immunology 2020; (11()):971 doi:10.3389/fimmu.2020.00971.

    PMID: 32670263
  16. 16

    Efficacy and Safety of Anakinra in Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Single-Center Real-Life Experience.

    Ocak T, Köse HN, Yağız B, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(5)) doi:10.3390/medicina61050792.

    PMID: 40428750
  17. 17

    Canakinumab for the treatment of familial Mediterranean fever.

    Ozdogan H, Ugurlu S

    Expert review of clinical immunology 2017; (13(5)):393-404 doi:10.1080/1744666X.2017.1313116.

    PMID: 28362189
  18. 18

    Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy.

    Aiello A, Mariano EE, Prada M, et al.

    Journal of market access & health policy 2023; (11(1)):2176091 doi:10.1080/20016689.2023.2176091.

    PMID: 36819891
  19. 19

    Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.

    Atas N, Eroglu GA, Sodan HN, et al.

    Clinical and experimental rheumatology 2021; (39 Suppl 132(5)):30-36 doi:10.55563/clinexprheumatol/815tdt.

    PMID: 34251317
  20. 20

    Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.

    Babaoglu H, Varan O, Kucuk H, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2020; (26(1)):7-13 doi:10.1097/RHU.0000000000000873.

    PMID: 30048391

This page provides educational information about advanced treatments for FMF. It does not replace professional medical advice. Always consult your rheumatologist or healthcare provider before making changes to your treatment plan.

Get notified when new evidence is published on Familial Mediterranean fever.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.